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Members of the nuclear receptor superfamily have vital roles in regulating immunity and inﬂammation. The founding member,
glucocorticoid receptor (GR), is the prototype to demonstrate immunomodulation via transrepression of the AP-1 and NF-κB
signaling pathways. Peroxisome proliferator-activated receptors (PPARs) have emerged as key regulators of inﬂammation. This
review examines the history and current advances in nuclear receptor regulation of inﬂammation by the crosstalk with AP-1 and
NF-κB signaling, focusing on the roles of GR and PPARs. A better understanding of the molecular mechanism by which nuclear
receptors inhibit proinﬂammatorysignaling pathways will enable novel therapies to treat chronic inﬂammation.
1.Introduction
The nuclear receptor (NR) superfamily comprises struc-
turally conserved, ligand-activated transcription regulators
thatplaycriticalrolesindevelopmentandhomeostasis[1,2].
In the immune system, it integrates both inﬂammatory and
metabolic signals to maintain homeostasis via positive and
negative regulation of gene expression [3, 4]. The immuno-
modulatory actions of NRs are regulated by ligands such
as glucocorticoids, the widely prescribed anti-inﬂammatory
drug [5]. Based on ligands, NRs are grouped into three sub-
families. The ﬁrst subfamily is the classic endocrine receptors
for steroid hormones, thyroid hormones, and vitamin A
a n dDd e r i v a t i v e s .T h es e c o n ds u b f a m i l yi st h eo r p h a nN R s
that share the common structural features of the endocrine
receptors, buttheirligands havenot beenidentiﬁedyet. Over
the past decade, a growing number of orphan receptors are
“adopted” through the identiﬁcation of dietary lipids and
metabolites as the ligands. These adopted orphan receptors
comprise the third subfamily that regulates a wide range of
transcriptional programs for tissue homeostasis.
Depending on ligand availability and promoter context,
NRs function both as positive and negative transcriptional
regulators. Initially, NRs were thought to be transcriptional
activators upon ligand binding [6]. Later studies show that
NRs can also repress transcription. The ﬁrst example is the
ﬁnding that estrogen receptor (ER) inhibits the prolactin
gene when its positive regulatory elements are removed
from the promoter [7]. It has now been established that
the negative regulation by NRs is crucially important in
physiology and diseases [3, 8]. Genome-wide studies show
that almost half of ER-target genes are inhibited by estradiol,
partially through the association with negative estrogen
response elements [9]. Negative glucocorticoid response
elements were also well described [8]. Recently, Surjit and
colleagues have identiﬁed novel negative response elements
for ligand-bound GRs, which are responsible for direct re-
pression of over 1000 genes [10]. Additionally, negative re-
gulation by NRs often occurs without direction interaction
with cis regulatory elements. Instead, NRs can repress trans-
cription via direct interactions with other transcription fac-
tors, termed transrepression.2 PPAR Research
NR transrepression pathways play a pivotal role in mod-
ulating inﬂammation. Glucocorticoids are widely prescribed
drugs to treat autoimmune and inﬂammatory diseases, and
their actions through GR serve as the prototype of NR
transrepression. Targets for nonsteroidal anti-inﬂammatory
drugs(NSAIDs),peroxisomeproliferator-activatedreceptors
(PPARs), are emerging as key regulators of the immune sys-
tem [11]. The spectrum of transrepression pathways is ex-
panding. Recently, 5-androgen-3β,1 7 β-diol (ADIOL) has
been characterized as an endogenous estrogen receptor (ER)
β ligand to suppress inﬂammatory responses of microglia
andastrocytesbyrecruitmentofCtBPcorepressorcomplexes
[12]. Though highly eﬀective in combating both acute and
chronicinﬂammatory diseases,glucocorticoid-basedtherapy
has profound side eﬀects during chronic administration,
which is due to the multiple physiological roles of the hor-
mone. For this reason, PPARs have attracted growing atten-
tion for drug development. Understanding the molecular
details of NR-mediated repression is critical for therapeutic
improvement. This paper summarizes the last two decades
ofresearch toelucidatethemolecularmechanisms ofGRand
PPAR transrepression pathwaysandtodelineatethecrosstalk
between these two pathways.
2.GeneralSignaling Pathwaysin Inﬂammation
Inﬂammation is a biological response in which the body re-
cruits immune cells to sites of infection, injury, or autoim-
mune reaction to initiate tissue repair processes [3, 13]. The
homeostasis of the immune system is of pivotal importance
to human health. Chronic inﬂammation is strongly associ-
ated with a broad range of pathological conditions, such as
rheumatoid arthritis, inﬂammatory bowel diseases, asthma,
diabetes, and atherosclerosis.
Activatorprotein-1(AP-1)andnuclearfactor-κB(NF - κB)
are among master regulators of inﬂammation. They respond
to a remarkable variety of external and internal stimuli and
control the expression of a diverse array of genes involved in
inﬂammation, cell proliferation, diﬀerentiation, and survival
[14–16].
AP-1 is a group of dimeric basic region-leucine zipper
(bZIP) proteins that includes four subfamilies: Jun (c-Jun,
JunB, and JunD), Fos (c-Fos, FosB, Fra-1, and Fra-2), Maf,
and ATF, which recognize either TPA- (12-O-tetradecanoyl-
phorbol-13-acetate-) response elements or cAMP-response
elements (CRE) [16]. Depending on cell types, the major
form of cellular AP-1 is either the Jun-Fos heterodimer or
the Jun-Jun homodimer. The AP-1 signaling pathway is reg-
ulated at several levels: ﬁrst, regulation of Jun and Fos tran-
scription and mRNAturnover;second, regulation ofJun and
Fos protein turnover; third, posttranslational modiﬁcations
of Jun and Fos proteins that modulate their transcription
activity; fourth, recruitment of other proteins that can either
synergize or interfere with AP-1 activity, as exempliﬁed by
GR [17, 18]. The transcription of the Jun and Fos family
genes can be stimulated by cytokines or other physiologi-
cal signals in an MAP kinase-dependent manner [19, 20]
(Figure 1).Jun andFosthenform theheterodimer toactivate
or repress their target genes.
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Figure1:Transcriptionalcontrolofinﬂammation.Signaltransduc-
tionofproinﬂammatorycytokines,forexample, TNF-α and/orLPS
signalsleadtoactivationofIKKcomplextoliberatecytosolicNF-κB
from inhibition via ubiquitination and degradation of IκBα. These
stimuliactivate the JNK-AP-1 pathway.Coordinated actions of NF-
κB and AP-1 propagate inﬂammation via promoting transcription
of cytokines, chemokines, and other proinﬂammatorygenes.
The NF-κB transcription factor family in mammals con-
sists of ﬁve protein subunits, p65 (RelA), RelB, c-Rel,
p105/p50 (NF-κB1), and p100/p52 (NF-κB2). These sub-
units form hetero- or homodimeric transcription complexes
withdistinct activities [14].The p65(RelA)/p50heterodimer
represents the most abundant form of NF-κB[ 14, 15]. In
quiescent cells, NF-κB retains in the cytoplasm by binding
to the inhibitor of κB( I κB) family proteins (IκBα,I κBβ,
and IκBε) or the precursor Rel proteins (p105 and p100)
[14]. A great variety of stimuli, including proinﬂammatory
cytokines and bacterial endotoxin lipopolysaccharide (LPS),
activate the heterotrimeric IKK (IκB kinase) complex, which
serves as a critical node that integrates diverse upstream
signals. Lysine (K63)-linked and/or the carboxy-terminal
glycine (G76)-linked linear polyubiquitinationof IKKγ (also
known as NEMO, NF-κB essential modulator) promotes
phosphorylation of the complex, leading to either phospho-
rylation, polyubiquitination and subsequent proteasomal
degradation of IκBs, or proteolytic processing of p100 into
p52 [21, 22]. Consequently, NF-κB is released from inhibi-
tion and mobilized to the nucleus (Figure 1). In addition to
protein processing of inhibitory modules, posttranslational
modiﬁcations of the p65 subunit also modulate release and
nuclear translocation of NF-κB[ 21]. Of note, following
IκBα degradation, phosphorylation of p65 at S276 regulates
DNA binding, dimerization, and recruitment of p300/CBP
(CREB-binding protein) coactivator complexes [21, 23].
Acetylation of p65, probably catalyzed by p300/CBP or
otherlysineacetylases, enhancestranscriptional activity[24].
Nuclear NF-κB binds directly to and activates target genes in
concert with other transcription factors [25, 26].
TheterminationofNF-κBsignaling iscontrolledbymul-
tiple mechanisms. NF-κB induces expression of inhibitory
proteins (such as IκBα and A20) and a subset of microRNA
species, which in turn inhibit NF-κB expression or activityPPAR Research 3
[14, 27]. Single-cell studies indicate that negative feedback
inhibition by IκBα does not terminate the signaling abruptly
but generates cyclic presence of NF-κBi nt h en u c l e u s[ 28].
Another negative feedback loop is that induction of the
deubiquitinase A20 leads to the inactivation of IKK [29].
Positive feedback loops are important for robust oscillation
of NF-κB signaling. TNF-α cannot only initiate NF-κB
signaling, but also promote a secondary wave of NF-κB
responses induced by LPS-TLR4 signaling [30], therefore
producing positive feedback. In addition to the feedback
transcriptional regulation, posttranslational modiﬁcations
of NF-κBa l s oc o n t r i b u t et ot e m p o r o s p a t i a lr e g u l a t i o n .F o r
example, deacetylation of p65 by histone deacetylase 3
(HDAC3) promotes the interaction between nuclear IκBα
and NF-κB, resulting in nuclear export of the complex [31].
Inﬂammation is under the combinatorial transcriptional
control of NF-κB and AP-1 signaling pathways. Proinﬂam-
matory cytokines, such as tumor necrosis factor-α (TNF-α)
and interleukin-1β (IL-1β), induceAP-1 signaling via MAPK
cascades and activate NF-κB signaling by ubiquitination
and degradation of IκBα [3, 13]( Figure 1). AP-1 and NF-κB
coordinate the transcriptional reprogramming of immune
cells by stimulating expression of proinﬂammatory cytok-
ines, chemokines, adhesion molecules, matrix metallopro-
teases, and others. Sustained inﬂammation would be detri-
mental to tissue homeostasis, and multiple mechanisms have
evolved to terminate inﬂammation. Apart from feedback
transcriptional and posttranslational regulation mentioned
above, a preeminent mechanism is NR-mediated transre-
pression.
3.MolecularMechanisms of
GRTransrepression
3.1. Direct Interactions between GR and AP-1. GR is a proto-
typical member of the NR superfamily, initially identiﬁed as
a potent transcription activator [1, 32]. At that time, it was
considered that all the physiological eﬀects of GR are medi-
ated through gene induction [6]. This view was challenged a
few years later by the discoveries that GR represses transcrip-
tion of a variety of genes, including proopiomelanocortin
(POMC)gene,vianegative glucocorticoidresponse elements
(nGREs) [33, 34]. The binding of liganded GR to the nGRE
has been implicated in transcriptional repression of only
several proinﬂammatory genes [35]. As discussed below, the
suppressive eﬀects of glucocorticoids on inﬂammation are
largely independent of the DNA-binding activity of GR, but
viaatethering mechanism referred toastransrepression. The
discovery of GR-mediated inhibition of AP-1 transcriptional
activity [34, 36, 37] is the ﬁrst example of transrepression
(Figure 2(a)).
Transcription of the collagenase type I gene is stimulated
by AP-1 [38, 39] and repressed by liganded GR [40, 41],
which was used to explore the molecular mechanism of GR-
mediated repression. Schule and his colleagues identiﬁed
the inhibitory eﬀects of dexamethasone (Dex, a synthetic
GR ligand)-activated GR on both synthetic and endogenous
promoters containing binding sites for AP-1 in diﬀerent cell
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Figure 2: Molecular mechanisms of GR transrepression of AP-1
andNF-κB. (a)Ligand-activated GRistethered toAP-1andrecruits
transcriptional mediators/intermediary factor 2 (TIF-2) to inhibit
transcription of AP-1 target genes. (b) Ligand-activated GR bound
to NF-κB interferes with recruitment of NF-κBS e r 2C T Dk i n a s e ,
positive transcription elongation factor b (P-TEFb), which is re-
quired for the transcription of proinﬂammatory genes. (c) Ligand-
activated GR induces synthesis of IκBα,t h e r e b yb l o c k i n gN F - κB
nuclear translocation.
types[34].TheGRinhibitionisindependentoftheglucocor-
ticoid response element (GRE) but strongly associated with
AP-1-binding sites. Nevertheless, the authors did not per-
form mutationanalysis ofthe AP-1 sites to provide the direct
evidence for the requirement of AP-1 sites for GR-mediated
repression. Mutation analysis of GR identiﬁed that both
the ligand-binding domain (LBD) and the DNA-binding
domain (DBD) are required for repression of AP-1 activity.
This study is complemented by Jonat et al. showing that
cotreatment with Dex nearly abolished TPA induction of
collagenase proteins [36]. Transrepression is distinct from
transactivation and involvesthedirect interactionwithAP-1.
The conclusion is corroborated by a follow-up study report-
ing that the repression is mediated by GR monomers rather
than transcriptional active dimers [42]. Furthermore, the
characterization of dimerization-deﬁcient GR (GRdim/dim)
knock-in mice reveals that transrepression of AP-1 remains
intact while transactivation of tyrosine aminotransferase
(TAT) is impaired [43]. The in vitro evidence for the direct
interaction between GR and AP-1 was also reported by Yang-
Yen et al. [37] .H o w e v e r ,J o n a te ta l .a n dY a n g - Y e ne ta l .
disagreed on whether the DNA binding property of AP-1 is
impaired by physical association with activated GR, which
might be attributed to their diﬀerent sources of GR and AP-
1 proteins. Human cell lysates show enhanced association4 PPAR Research
between AP-1 and its target DNAsequence probablybecause
of enhanced c-Jun transcription following Dex treatment
[36],which isimpossibleintheinvitroassay system. Alterna-
tively, it could be due to the diﬀerent compositions of AP-1
used in their assays. Yang-Yen et al. used c-Jun monomers,
instead of c-Jun/c-Fos heterodimers, in the in vitro assay. A
follow-upstudyreportedthatinvitro synthesized GRsdonot
interfere the binding of c-Jun/c-Fos heterodimers or puriﬁed
AP-1 in vitro [44].
Despite slight discrepancies in the detail, the reports
aboveuniformly unravelanovelmechanism of GR-mediated
repression via a direct interaction with a transcription factor,
AP-1, butnot direct association with DNA.The essential fea-
tures of crosstalk between NRs and AP-1 signaling pathways
seems to be highly conserved, since RARαand TRα have also
been shown to antagonize AP-1 signaling following the same
mechanism [45, 46]. NR-mediated regulation of AP-1 is
likelytobedynamicand dependentonthepromotercontext.
AlthoughGRIP-1/TIF-2 is a coactivator for both GR and TR,
a study has shown that GRIP-1/TIF-2 can potentiate GR-
mediatedtransrepression ofthecollagenase-3geneinhuman
osteosarcoma cellsbuthasnoeﬀectonthetransrepression by
TR [47]( Figure 2(a)).
3.2. Direct Interactions between GR and NF-κB. The discov-
ery of GR inhibition of AP-1 sparked the exploration of
whether NF-κB is also a target of GR. A few groups reported
that, similar to AP-1, activated GR inhibited NF-κB-medi-
ated transcription of proinﬂammatory genes, including IL-
6 and ICAM-1, via direct physical interaction with the p65
subunitofNF-κB[48–50].NissenandYamamotoscrutinized
themolecular detailsofGR inhibition by mapping regions of
both GR and p65 that are involved in their association and
probing the biochemical composition of RNA polymerase
II (pol II) complexes at the promoters of IL-8, ICAM-1
and IκBα genes via chromatin immunoprecipitation (ChIP)
assays [51]. In vitro assays identiﬁed that both the DBD
and the LBD of GR interact with the dimerization domain
of p65. Interestingly, the same regions in GR are involved
in the interaction with AP-1, suggesting the existence of
a common repression complex and a conserved repression
mechanism for AP-1 and NF-κB. The large subunit of
RNA polymerase II has a unique carboxyl-terminal domain
(CTD) that comprises conserved YSPTSPS heptad repeats.
Phosphorylation of the heptad repeats at Ser2 is required for
transcription. ChIP data reveal that GR can interfere with
Ser2 phosphorylation of pol II CTD at the promoter regions
of IL-8 and ICAM-1 genes, whereas neither the binding of
NF-κB to DNA nor the assembly of preinitiation complexes
is aﬀected under repressing conditions. The phospho-Ser2
level at the IκBα promoter is unaﬀected by Dex. Thus,
GR represses NF-κB-stimulated transcription of a subset of
inﬂammatory genes by suppressing pol II CTD phosphory-
lation. Given that neither HDAC recruitment nor putative
Ser2 phosphatase has been identiﬁed, it will be important to
uncover the identity of corepressors of GR inhibition.
There are several diﬀerent but not mutually exclusive
explanations for GR-induced transrepression of NF-κB
signaling (Figure 2(b)). First, GR can antagonize with pro-
tein kinases that modify pol II CTD. Luecke and Yamamoto
reported that GR prevents the recruitment of the Ser2 CTD
kinase complex P-TEFb (positive transcription elongation
factor b) to the promoter of IL-8 but not IκBα, probably by
interfering the physical interaction between NF-κBa n dP -
TEFb [52]. Second, ligand-bound GR is likely to facilitate
another posttranslational modiﬁcation that competes with
phosphorylation of CTD [53]. Third, the speciﬁcity of GR
transrepression can be attributed to the composition of NF-
κB activation complexes. Activated GR also disrupts the NF-
κB/interferon regulatory factor (IRF) enhanceosomes that
are responsible for activation of a large set of TLR4- and
TLR9-dependent inﬂammatory genes [54, 55].
3.3. Regulation of IκBb yG R .Despite substantial evidence
to support the transrepression mechanism, it should be
cautiousto make a sweeping conclusionthat this mechanism
accounts for all the inhibitory eﬀects of GR on NF-κB.
The studies from Baldwin’s and Karin’s groups suggest that
glucocorticoids modulate NF-κB signaling by stimulating
transcription of the gene encoding the NF-κB inhibitor
protein—IκB[ 56, 57]( Figure 2(c)). Auphan and colleagues
have shown that glucocorticoids are potent inhibitors of NF-
κB activity in mouse immune organs and several lymphoma
cells [57]. Dex can abolish NF-κBD N A - b i n d i n ga c t i v i t y
through GR in human lymphoma Jurkat cells. Additionally,
Dex-activated GR also induces the synthesis of IκBα,r e s u l t -
ing in the sequestration of NF-κB in the cytoplasma. The
involvement of protein synthesis in the inhibition of NF-κB
signaling argues against direct interaction between GR and
NF-κB in lymphoma cell lines.
However, GR-induced synthesis of IκBα is dispensable
for transrepression of NF-κB signaling. Several studies
have demonstrated that transrepression and transactivation
properties of GR can be separated [42, 58]. A dimerization-
defective mutant of human GR that fails to induce IκBα
expression can eﬀectively inhibit transcriptional activity of
NF-κB. Moreover, some glucocorticoid analogs can enhance
the synthesis of IκBα but fail to repress NF-κBa c t i v i t y .T h e
ﬁrst in vivo evidence came from further characterization
of the dimerization-deﬁcient mutant GR (A458T) knock-in
mouse model which had been used to demonstrate that GR
transrepresses AP-1 signaling despite loss of transactivation
in vivo[43,59].GR(A458T)caneﬀectivelyrepressbothlocal
and systemic inﬂammatory responses via repressing NF-κB
in the absence of DNA binding. Nevertheless, studies using
GR DBD mutants suggest that GR-mediated transrepression
of AP-1 and NF-κB signaling may involve diﬀerent mecha-
nisms [60]. A point mutation in the second zinc ﬁnger of
DBD (R488Q) abolishes the ability of GR to repress a subset
of NF-κBtarget genesbutnot AP-1-luciferase report activity.
4.Molecular Mechanisms of
PPAR Transrepression
PPARs are adopted NRs that modulate metabolism and in-
ﬂammation [3, 61]. There are three types of PPAR isoforms:PPAR Research 5
α, δ/β,a n dγ, with distinct biological functions. Previous
studies have uncovered multiple mechanisms by which
PPARssuppressproinﬂammatory geneexpression, including
theinhibition ofNF-κBand AP-1 signaling pathways and the
retention of corepressor complexes.
4.1. PPAR Inhibition on AP-1 and NF-κB. It has been re-
ported that PPARs suppress inﬂammation by inhibiting the
activity of other transcription factors, including AP-1 and
NF-κB[ 11]. Forexample, PPARαinhibits expression ofIL-6,
prostaglandin, and cyclooxygenase-2 (COX-2)via repression
of NF-κB signaling in aortic smooth muscle cells, thus pos-
sibly reducing the risk for atherosclerosis [62]. PPARγ can
attenuatemacrophageactivityviaantagonizingAP-1,NF-κB,
a n dS T A T 1 ,a sr e v e a l e db yt r a n s c r i p t i o nr e p o r t e ra s s a y s[ 63].
Delerive and colleagues characterized direct interactions
of PPARα with AP-1 and NF-κB[ 64]( F i g u r e s3(a)-3(b)).
PPARα inhibits vascular inﬂammation in arotic smooth
muscle cells by physical interactions with c-Jun and p65. In-
terestingly, the regions of c-Jun and p65 that bind to PPARα
also interact with GR. On the other hand, the synthetic
PPARα ligand called ﬁbrate can induce the expression
of IκBα in both smooth muscle cells and hepatocytes,
resulting in sequestration of NF-κB in the cytoplasma and
reduction in its DNA-binding ability. These ﬁndings are
corroborated by the results from PPARα-null mice, showing
that the induction of IκBα expression is PPARα-dependent
[65]. Therefore, PPARα and GR appear to share similar
mechanisms to repress AP-1 and NF-κB, respectively.
PPARγ transrepression pathways also impinge on AP-1
and NF-κB. PPARγ has been shown to inhibit AP-1 associ-
ation with DNA and activation in vascular endothelial cells
and lungs, respectively [66, 67]. Modulated by physiological
ligands from oxidized low-density lipoproteins (oxLDL),
PPARγ can also inhibit interleukin-12 (IL-12) production in
marcophages through direct interaction with NF-κB[ 68].
4.2. PPARγ and Sumoylation-Dependent Association with
Corepressor Complexes. In addition to transrepressing spe-
ciﬁc transcriptional activators, PPARs have been demon-
strated to prevent the clearance of corepressor complexes
at the promoter regions (Figure 3(c)). The NR corepressor
(NCoR)/SMRT-HDAC3 corepressor complex is recruited by
several unliganded NRs to mediate transcriptional repres-
sion [69–71]. Recent data show that NCoR/SMRT-HDAC3
corepressor complexes are also required for basal repression
of a subset of AP-1 and NF-κB target genes through asso-
ciation with inhibitory homodimers (cJun-cJun and p50-
p50), respectively [72–74]. Using the inducible nitric oxide
synthase (iNOS) gene in mouse macrophages as a model,
Pascual and colleagues uncovered a novel transrepression
pathway that PPARγ represses this NF-κBt a r g e tg e n ev i a
association with NCoR, leading to stabilization of the
corepressor complexes [75]. Ligand-dependent activation
of PPARγ is associated with SUMOylation of the ligand-
binding domain (LBD), which promotes the physical inter-
action between PPARγ and NCoR. This direct interaction
targets the NR to the NCoR-HDAC3 corepressor complexes
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Figure 3: Molecular mechanisms of PPAR transrepression path-
ways. (a-b) Ligand-activated PPAR (α or γ) inhibits the activities
of AP-1 and NF-κB through direct interactions with the c-Jun
subunit and the p65 subunit, respectively. (c) On ligand binding,
PPARγ is sumoylated and blocks ubiquitin-dependent proteasomal
degradation of the NCoR corepressor complexes at NF-κB-binding
sites. The presence of the corepressor complexes prevents the
recruitment of transcriptionally active NF-κB, leading to inhibition
of inﬂammatorygene expression.
at proinﬂammatory gene promoters and thus prevents LPS-
induced recruitment of the ubiquitination/19S proteosome
machinery to remove the corepressor complexes. Conse-
quently, the impaired clearance of the NCoR/SMRT-HDAC3
complexes blocks the exchange of repressive homodimers for
active heterodimers of NF-κB[ 72]. The corepressor com-
plexes are also involved in the regulation of AP-1 target
genes in macrophages [73], which is probably inﬂuenced
by this sumoylation-dependent transpression pathway. Like-
wise, liver X receptors (LXRs) also adopt this transrepression
mechanism [76]. Taken together, these studies delineate a
molecular pathway featured on NR-mediated stabilization of
corepressor complexes.
5.CrosstalkbetweenPPARsandGR
TransrepressionPathways
The extensive crosstalk between PPARs and GR in immuno-
modulation has emerged as a key strategy to combat chronic
inﬂammatory diseases [54, 77]. Genome-wide gene expres-
sion proﬁling data shows that GR and PPARγ function in a
combinatorial manner to repress LPS-responsive genes [54],
indicating diﬀerentialtransrepression pathwaysforthese two
NRs (see Sections 3.2 and 4.2). In contrast, PPARα and GR
seem to share several common features of NF-κBa n dA P - 16 PPAR Research
inhibition. Simultaneous activation of both NRs lead to
corepression of NF-κBt a r g e tg e n e s[ 77]. PPARα can directly
associate with GR. This interaction enhances GR transre-
pression and, at the same time, blocks the recruitment of
GR to glucocorticoid-responsive elements and thus inhibits
transactivation of GR target genes. The unexpected ﬁnding
that PPARα can prevent the GR-mediated transactivation
implies that coadministration of glucocorticoids and PPARα
ligands can enhance the immune-modulatory eﬀects and
reduce the side eﬀects caused by glucocorticoids [77, 78].
6.Conclusionsand FuturePerspectives
Decades of research have characterized multiple molecular
pathways of NR-mediated negative regulation of inﬂamma-
tory genes. In this framework, on binding to their speciﬁc
ligands, NRs have at least two diﬀerent, but not mutually
exclusive, mechanisms to inhibit transcription. First, NRs
can directly inhibit the activities of NF-κBa n dA P - 1 .I n
addition, combinatorial actions of diﬀerent NRs can opti-
mize both the strength and speciﬁcity of transrepression.
For example, PPARα and GR can function synergistically to
r epr es sth ee xpr es s i onofi n ﬂ a m m a t orygen esa sw ella stra n s -
actionactivity of theirown [77].Second, NRs can induce the
expressionofgenesthatinhibitinﬂammatory signalingpath-
ways. Transrepression of AP-1 and NF-κB signaling path-
ways results in decrease in cytokine production and other
proinﬂammatory responses, bringing the immune system
back to homeostasis.
However, numerous questions remain to be addressed.
First, we have focused on several NR transrepression path-
ways to illustrate some general principles, but the composi-
tion and dynamics of the underlying signaling circuit have
yet to be fully uncovered. In addition to discovering novel
mechanisms, further studies should delineate the relation-
shipamong existingpathways.Forexample,PPARγ probably
also interferes with phosphorylation of the CTD of RNA
polymerase II; likewise, GR and PPARα are possible to
stabilize corepressor complexes associated with inﬂamma-
tory genes. Several studies have implied that corepressor
complexes can function as a checkpoint for transcriptional
control [73, 75]. Here, we would elaborate on the checkpoint
by proposing the following model: Ligand-bound NRs are
targeted to inﬂammatory genes by activated NF-κBo rA P - 1
and then halt transcription at the checkpoint by (1) stabi-
lizing NCoR/SMRT-HDAC corepressor complexes, (2) pre-
ventingassociation ofactive transcription factors and coacti-
vators, (3) maintaining the inhibitory histone modiﬁcations,
and (4) modifying the CTD of RNA polymerase II. The
completion of all these molecular events may contribute to
transrepression of inﬂammatory genes.
Second,givenevidencethat diﬀerent NRstarget diﬀerent
subsets of inﬂammatory genes [54], it will be important to
deﬁne these subgroups and assess the overlapping function
of NRs. In addition, the transrepression pathways exhibit
tissue speciﬁcity, such as diﬀerent GR responses in immune
and nonimmune cells. Recentadvances by Cidlowski’s group
and others have shown that multiple isoforms of GR can be
generated from the sole GR gene via alternative splicing and
selective translational initiation, which exhibit tissue-speciﬁc
distribution and diﬀerent regulatory mechanisms [79]. NRs
also recruit diﬀerent coregulators and/or other transcription
factors to target speciﬁc gene sets, as inferred from cur-
rent studies. The identiﬁcation of these NR isoforms, co-
regulators, and histone modiﬁcations is not only important
for understanding NR regulation of inﬂammation, but also
beneﬁcial for therapeutic intervention of inﬂammation.
Third, glucocorticoids are released from adrenal glands
in circadian and ultradian modes to modulate inﬂammatory
responses. Ultradian hormone release stimulates cyclic GR-
mediated transcriptional regulation [80]. Whether this tem-
poral regulation might be relevant to GR-mediated transre-
pression, whether this could be observed in other endocrine
or adopted NRs, and whether pulse administration can im-
prove current clinical protocol are poorly studied. A better
understanding of temporal regulation of NR transrepression
pathways and their physiological signiﬁcance will bring
profound clinical beneﬁts.
Finally, chronic inﬂammation is associated with various
metabolicdiseases,suchascardiovasculardiseases,typeIIdi-
abetes, and obesity [81, 82]. Synthetic NR ligands have been
widelyusedtocontrolchronicinﬂammation. Asdietarylipid
and metabolites can serve as endogenous NR ligands, an
interesting question is whether the body’s metabolic state
impinges on the immune system via NR signaling.
In closing, inﬂammation is integral to a complex system
that maintains the body’s homeostasis. Unraveling temporal
and spatial regulation of inﬂammation by NRs using a com-
bination of biochemical, genetic, genomic, and proteomic
tools will aid in the design of novel therapies for inﬂamma-
tory diseases.
Acknowledgments
The authors thank Yao Wu for inspiring discussion. This
work was supported by American Diabetes Association Jun-
ior Faculty Award (1-10-JF-56), NIH RO1-DK089098, NIH
P30-DK34989 to X. Yang, and fellowship from the China
Scholarship Council-Yale World Scholars in the Biomedical
Sciences to M.-D. Li.
References
[ 1 ]R .M .E v a n s ,“ T h es t e r o i da n dt h y r o i dh o r m o n er e c e p t o rs u -
perfamily,” Science, vol. 240, no. 4854, pp. 889–895, 1988.
[2] D. J. Mangelsdorf, C. Thummel, M. Beato et al., “The nuclear
receptor super-family: the second decade,” Cell, vol. 83, no. 6,
pp. 835–839, 1995.
[3] C. K. Glass and K. Saijo, “Nuclear receptor transrepression
pathways that regulate inﬂammation in macrophages and T
cells,” Nature Reviews Immunology,vol.10,no.5,pp. 365–376,
2010.
[4] G. Pascual and C. K. Glass, “Nuclear receptors versus inﬂam-
mation:mechanismsoftransrepression,”TrendsinEndocrinol-
ogy and Metabolism, vol. 17, no. 8, pp. 321–327, 2006.
[5] J. Glyn, “The discovery and early use of cortisone,” Journal
of the Royal Society of Medicine, vol. 91, no. 10, pp. 513–517,
1998.PPAR Research 7
[6] K. R. Yamamoto, “Steroid receptor regulated transcription of
speciﬁc genes and gene networks,” Annual review of genetics,
vol. 19, pp. 209–252, 1985.
[7] S. Adler, M. L. Waterman, X. He, and M. G. Rosenfeld,
“Steroid receptor-mediated inhibition of rat prolactin gene
expression does not require the receptor DNA-binding do-
main,” Cell, vol. 52, no. 5, pp. 685–695, 1988.
[ 8 ] G .M .S a n t o s ,L .F a i r a l l ,a n dJ .W .R .S c h w a b e ,“ N e g a t i v er e g u -
lation by nuclear receptors: a plethora of mechanisms,” Trends
in Endocrinology and Metabolism, vol. 22, no. 3, pp. 87–93,
2011.
[9] M. Kininis and W. L. Kraus, “A global view of transcriptional
regulation by nuclear receptors: gene expression, factor local-
ization, and DNA sequence analysis,”Nuclear Receptor Signal-
ing, vol. 6, article e005, 2008.
[10] M.S u r j it ,K .P .G ant i,A .M u khe r j ie tal. ,“ W id e sp r e adne g at i v e
response elements mediate direct repression by agonist-
liganded glucocorticoid receptor,” Cell, vol. 145, no. 2, pp.
224–241, 2011.
[11] M.RicoteandC.K.Glass,“PPARsandmolecularmechanisms
of transrepression,” Biochimica et Biophysica Acta, vol. 1771,
no. 8, pp. 926–935, 2007.
[ 1 2 ]K .S a i j o ,J .G .C o l l i e r ,A .C .L i ,J .A .K a t z e n e l l e n b o g e n ,a n dC .
K. Glass, “An ADIOL-ERβ-CtBP transrepression pathway
negatively regulates microglia-mediated inﬂammation,” Cell,
vol. 145, no. 4, pp. 584–595, 2011.
[13] I. M. E. Beck, W.V. Berghe, L. Vermeulen, K. R. Yamamoto,G.
Haegeman, and K. De Bosscher, “Crosstalk in inﬂammation:
the interplay of glucocorticoid receptor-based mechanisms
and kinasesand phosphatases,”Endocrine Reviews, vol.30, no.
7, pp. 830–882, 2009.
[14] A. Oeckinghaus and S. Ghosh, “The NF-kappaB family of
transcription factors and its regulation,” Cold Spring Harbor
Perspectives in Biology, vol. 1, no. 4, Article ID a000034, 2009.
[ 1 5 ]M .S .H a y d e na n dS .G h o s h ,“ S i g n a l i n gt oN F - κB,” Genes and
Development, vol. 18, no. 18, pp. 2195–2224, 2004.
[16] E. Shaulian and M. Karin, “AP-1 as a regulator of cell life and
death,” Nature Cell Biology, vol.4, no. 5, pp. E131–E136, 2002.
[17] Y. Chinenov and T. K. Kerppola, “Close encounters of many
kinds: Fos-Jun interactions that mediate transcription regu-
latory speciﬁcity,” Oncogene, vol. 20, no. 19, pp. 2438–2452,
2001.
[18] P. Angel and M. Karin, “The role of Jun, Fos and the AP-1
complex in cell-proliferation and transformation,”Biochimica
et Biophysica Acta, vol. 1072, no. 2-3, pp. 129–157, 1991.
[19] M. Karin, “The regulation of AP-1 activity by mitogen-acti-
vated protein kinases,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,v o l .
270, no. 28, pp. 16483–16486, 1995.
[20] M. Karin, “The regulation of AP-1 activity by mitogen-acti-
vated protein kinases,” Philosophical Transactions of the Royal
Society B, vol. 351, no. 1336, pp. 127–134, 1996.
[21] M. S. Hayden and S. Ghosh, “Shared Principles in NF-κBS i g -
naling,” Cell, vol. 132, no. 3, pp. 344–362, 2008.
[22] F. Tokunaga, S. I. Sakata, Y. Saeki et al., “Involvement of linear
polyubiquitylation of NEMO in NF-κBa c t i v a t i o n , ”Nature
Cell Biology, vol. 11, no. 2, pp. 123–132, 2009.
[23] L. F. Chen and W. C. Greene, “Shaping the nuclear action of
NF-κB,” Nature Reviews Molecular Cell Biology,v o l .5 ,n o .5 ,
pp. 392–401, 2004.
[24] L. F. Chen, Y. Mu, and W. C. Greene, “Acetylation of RelA at
discrete sites regulates distinct nuclear functions of NF-κB,”
EMBO Journal, vol. 21, no. 23, pp. 6539–6548, 2002.
[25] D. Thanos and T. Maniatis, “Virus induction of human IFNβ
gene expression requires the assembly of an enhanceosome,”
Cell, vol. 83, no. 7, pp. 1091–1100, 1995.
[26] A. Richmond, “NF-κB, chemokine gene transcription and
tumourgrowth,”Nature ReviewsImmunology,v ol.2,no .9,pp .
664–674, 2002.
[27] R. M. O’Connell, D. S. Rao, A. A. Chaudhuri, and D. Balti-
more, “Physiologicaland pathologicalroles for microRNAs in
the immune system,” Nature Reviews Immunology,v o l .1 0 ,n o .
2, pp. 111–122, 2010.
[28] G. L. Hager, J. G. McNally, and T. Misteli, “Transcription
dynamics,” Molecular Cell, vol. 35, no. 6, pp. 741–753, 2009.
[29] M. Marcello and M. R. H. White, “Spatial and temporal infor-
mation coding and noise in the NF-κBs y s t e m , ”Biochemical
Society Transactions, vol. 38, no. 5, pp. 1247–1250, 2010.
[30] T. K. Lee, E. M. Denny, J. C. Sanghvi et al., “A noisy paracrine
signal determines the cellular NF-κB response to lipopolysac-
charide,” Science Signaling, vol. 2, no. 93, p. ra65, 2009.
[31] L. F. Chen, W. Fischle, E. Verdin, and W. C. Greene, “Duration
of nuclear NF-κB action regulated by reversible acetylation,”
Science, vol. 293, no. 5535, pp. 1653–1657, 2001.
[32] V. Giguere, S. M. Hollenberg, M. G. Rosenfeld, and R. M.
Evans, “Functional domains of the human glucocorticoid
receptor,” Cell, vol. 46, no. 5, pp. 645–652, 1986.
[33] J.Drouin, M.Nemer, J.Charronet al.,“Tissue-speciﬁc activity
of the pro-opiomelanocortin(POMC) gene and repression by
glucocorticoids,” Genome,vol. 31, no. 2, pp. 510–519, 1989.
[34] R. Schule, P. Rangarajan, S. Kliewer et al., “Functional antag-
onism between oncoprotein c-Jun and the glucocorticoid
receptor,” Cell, vol. 62, no. 6, pp. 1217–1226, 1990.
[35] R. Newton and N. S. Holden, “Separating transrepression and
transactivation: a distressing divorce for the glucocorticoid
receptor?” Molecular Pharmacology, vol. 72, no. 4, pp. 799–
809, 2007.
[36] C. Jonat, H. J. Rahmsdorf, K. K. Park et al., “Antitumor pro-
motion and antiinﬂammation: down-modulation of AP-1
(Fos/Jun) activity by glucocorticoid hormone,” Cell, vol. 62,
no. 6, pp. 1189–1204, 1990.
[ 3 7 ]H .F .Y a n g - Y e n ,J .C .C h a m b a r d ,Y .L .S u ne ta l . ,“ T r a n -
scriptional interference between c-Jun and the glucocorticoid
receptor: mutual inhibition of DNA binding due to direct
protein-protein interaction,” Cell, vol. 62, no. 6, pp. 1205–
1215, 1990.
[38] P. Angel, M. Imagawa, R. Chiu et al., “Phorbol ester-inducible
genes contain a common cis element recognized by a TPA-
modulated trans-acting factor,” Cell, vol. 49, no. 6, pp. 729–
739, 1987.
[39] A. Schonthal,P.Herrlich, H. J.Rahmsdorf,andH. Ponta,“Re-
quirements for fos gene expression in the transcriptional
activation of collagenase by other oncogenes and phorbol
esters,” Cell, vol. 54, no. 3, pp. 325–334, 1988.
[ 4 0 ]F .R .W e i n e r ,M .J .C z a j a ,a n dD .M .J e ﬀerson, “The eﬀects of
d e x a m e t h a s o n eo ni nv i t r oc o l l a g e ng e n ee x p r e s s i o n , ”Journal
of Biological Chemistry, vol. 262, no. 15, pp. 6955–6958, 1987.
[41] C. E. Brinckerhoﬀ,I .M .P l u c i n s k a ,L .A .S h e l d o n ,a n dG .
T. O’Connor, “Half-life of synovial cell collagenase mRNA is
modulated by phorbol myristate acetate but not by all-trans-
retinoic acid or dexamethasone,” Biochemistry, vol. 25, no. 21,
pp. 6378–6384, 1986.
[42] S. Heck, M. Kullmann, A. Gast et al., “A distinct modulating
domain in glucocorticoid receptor monomers in the repres-
sion of activity of the transcription factor AP-1,” EMBO Jour-
nal, vol. 13, no. 17, pp. 4087–4095, 1994.8 PPAR Research
[43] H. M. Reichardt, K. H. Kaestner, J. Tuckermann et al., “DNA
binding of the glucocorticoid receptor is not essential for sur-
vival,” Cell, vol. 93, no. 4, pp. 531–541, 1998.
[44] H. Konig, H. Ponta, H. J. Rahmsdorf, and P. Herrlich,
“Interference between pathway-speciﬁc transcription factors:
glucocorticoids antagonize phorbol ester-induced AP-1 activ-
ity without altering AP-1 site occupation in vivo,” EMBO
Journal, vol. 11, no. 6, pp. 2241–2246, 1992.
[45] R.Schule,P.Rangarajan,N.Yanget al.,“Retinoic acidisa neg-
ative regulator of AP-1-responsive genes,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 88, no. 14, pp. 6092–6096, 1991.
[46] X. K. Zhang, K. N. Wills, M. Husmann, T. Hermann, and M.
Pfahl, “Novel pathway for thyroid hormone receptor action
through interaction with jun and fos oncogene activities,”
Molecular and Cellular Biology, vol. 11, no. 12, pp. 6016–6025,
1991.
[47] I. Rogatsky, K. A. Zarember, and K. R. Yamamoto, “Factor
recruitment and TIF2/GRIP1 corepressor activity at a col-
lagenase-3 response element that mediates regulation by
phorbol esters and hormones,”EMBO Journal, vol. 20, no. 21,
pp. 6071–6083, 2001.
[48] A. Ray and K. E. Prefontaine, “Physical association and func-
tional antagonism between the p65 subunit of transcription
factor NF-κB and the glucocorticoid receptor,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 91, no. 2, pp. 752–756, 1994.
[49] R. I. Scheinman, A. Gualberto, C. M. Jewell, J. A. Cidlowski,
and A. S. Baldwin, “Characterization of mechanisms involved
in transrepression of NF-κB by activated glucocorticoid
receptors,” Molecular and Cellular Biology,v o l .1 5 ,n o .2 ,p p .
943–953, 1995.
[50] E.Caldenhoven,J.Liden,S.Wissinketal.,“Negative cross-talk
between RelA and the glucocorticoid receptor: a possible me-
chanism for the antiinﬂammatory action of glucocorticoids,”
Molecular Endocrinology, vol. 9, no. 4, pp. 401–412, 1995.
[51] R. M. Nissenand K. R. Yamamoto,“The glucocorticoid recep-
tor inhibits NFκB by interfering with serine-2 phosphoryla-
tion of the RNA polymerase II carboxy-terminal domain,”
Genes and Development, vol. 14, no. 18, pp. 2314–2329, 2000.
[52] H. F. Luecke and K. R. Yamamoto, “The glucocorticoid recep-
tor blocks P-TEFb recruitment by NFκBt oe ﬀect promoter-
speciﬁc transcriptional repression,” Genes and Development,
vol. 19, no. 9, pp. 1116–1127, 2005.
[53] M.-D. Li and X. Yang, “O-GlcNAc transferase is involved in
glucocorticoid receptor-mediated transrepression,” In press.
[54] S.Ogawa,J.Lozach,C. Benneret al.,“Molecular determinants
of crosstalk between nuclear receptors and toll-like receptors,”
Cell, vol. 122, no. 5, pp. 707–721, 2005.
[55] T. H. Leung, A. Hoﬀmann,and D. Baltimore,“Onenucleotide
in a κB site can determine cofactor speciﬁcity for NF-κB
dimers,” Cell, vol. 118, no. 4, pp. 453–464, 2004.
[56] R. I. Scheinman,P.C. Cogswell, A. K.Lofquist,and A.S.Bald-
win, “Role of transcriptional activation of IκBα in mediation
of immunosuppression by glucocorticoids,” Science, vol. 270,
no. 5234, pp. 283–286, 1995.
[ 5 7 ]N .A u p h a n ,J .A .D i D o n a t o ,C .R o s e t t e ,A .H e l m b e r g ,a n dM .
Karin, “Immunosuppression by glucocorticoids: Inhibition of
NF-κB activity through induction of IκBs y n t h e s i s , ”Science,
vol. 270, no. 5234, pp. 286–290, 1995.
[58] S. Heck, K. Bender, M. Kullmann, M. G¨ ottlicher, P. Herrlich,
a n dA .C .B .C a t o ,“ I κBα-independent downregulation of NF-
κBa c t i vi tyb ygl u c o c o r t i c o i dr e c e p t o r , ”EMBO Journal, vol.16,
no. 15, pp. 4698–4707, 1997.
[59] H. M. Reichardt, J. P. Tuckermann, M. G¨ ottlicher et al., “Re-
pression of inﬂammatory responses in the absence of DNA
binding by the glucocorticoid receptor,” EMBO Journal,v o l .
20, no. 24, pp. 7168–7173, 2002.
[60] L. -G. Bladh, J. Lid´ e n ,K .D a h l m a n - W r i g h t ,M .R e i m e r s ,S .
Nilsson,andS.Okret,“Identiﬁcationofendogenousglucocor-
ticoid repressed genes diﬀerentially regulated by a glucocorti-
coid receptor mutant able to separate between nuclear factor-
κB and activator protein-1 repression,” Molecular Pharmacol-
ogy, vol. 67, no. 3, pp. 815–826, 2005.
[ 6 1 ]Y .Y a n g ,A .R .G o c k e ,A .L o v e t t - R a c k e ,P .D .D r e w ,a n dM .K .
Racke, “PPAR alpha regulation of the immune response and
autoimmune encephalomyelitis,” PPAR Research, vol. 2008,
Article ID 546753, 6 pages, 2008.
[62] B. Staels, W. Koenig, A. Habib et al., “Activation of human
aortic smooth-muscle cells is inhibited by PPARα but not by
PPARγ activators,” Nature, vol. 393, no. 6687, pp. 790–793,
1998.
[63] M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass,
“The peroxisome proliferator-activated receptor-γ is a nega-
tive regulator of macrophage activation,” Nature, vol. 391, no.
6662, pp. 79–82, 1998.
[64] P. Delerive, K. De Bosscher, S. Besnard et al., “Peroxisome
proliferator-activated receptor α negatively regulates the vas-
cular inﬂammatory gene response by negative cross-talk with
transcription factors NF-κBa n dA P - 1 , ”Journal of Biological
Chemistry, vol. 274, no. 45, pp. 32048–32054, 1999.
[65] P .D e le ri v e ,P .G e rv ois,J .C .F ru c hart ,andB .St ae ls,“ I nd u c t ion
of IκBα expression as a mechanism contributing to the anti-
inﬂammatory activities of peroxisome proliferator-activated
receptor-α activators,”Journal of Biological Chemistry,vol.275,
no. 47, pp. 36703–36707, 2000.
[66] P. Delerive, F. Martin-Nizard, G. Chinetti et al., “Peroxisome
proliferator-activated receptor activators inhibit thrombin-
induced endothelin-1production inhumanvascularendothe-
lial cells by inhibiting the activator protein-1 signaling path-
way,” Circulation Research, vol. 85, no. 5, pp. 394–402, 1999.
[ 6 7 ]B .Z i n g a r e l l i ,M .S h e e h a n ,P .W .H a k e ,M .O ’ C o n n o r ,A .D e n -
enberg, and J. A. Cook, “Peroxisome proliferator activator re-
ceptor-γ ligands,15-deoxy-Δ12,14-prostaglandin J2 and cigli-
tazone, reduce systemic inﬂammation in polymicrobial sepsis
by modulation of signal transduction pathways,” Journal of
Immunology, vol. 171, no. 12, pp. 6827–6837, 2003.
[68] S. W. Chung, B. Y. Kang, S. H. Kim et al., “Oxidized low
density lipoprotein inhibits interleukin-12 production in lipo-
polysaccharide-activated mouse macrophages via direct inter-
actions between peroxisome proliferator-activated receptor-γ
and nuclear factor-κB,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,v o l .
275, no. 42, pp. 32681–32687, 2000.
[ 6 9 ]J .D .C h e na n dR .M .E v a n s ,“ At r a n s c r i p t i o n a lc o - r e p r e s s o r
that interacts with nuclear hormone receptors,” Nature,v o l .
377, no. 6548, pp. 454–457, 1995.
[70] A. J. Horlein, A. M. Naar, T. Heinzel et al., “Ligand-independ-
ent repression by the thyroid hormone receptor mediated by a
nuclear receptor co-repressor,” Nature, vol. 377, no. 6548, pp.
397–404, 1995.
[ 7 1 ]J .L i ,J .W a n g ,J .W a n ge ta l . ,“ B o t hc o r e p r e s s o rp r o t e i n s
SMRT and N-CoR exist in large protein complexes containing
HDAC3,” EMBO Journal, vol.19,no. 16,pp. 4342–4350,2000.
[72] J. E. Hoberg, F. Yeung, and M. W. Mayo, “SMRT derepression
by the IκBk i n a s eα: a prerequisite to NF-κBt r a n s c r i p t i o na n d
survival,” Molecular Cell, vol. 16, no. 2, pp. 245–255, 2004.PPAR Research 9
[73] S. Ogawa, J. Lozach, K. Jepsen et al., “A nuclear receptor core-
pressor transcriptional checkpoint controlling activator pro-
tein 1-dependent gene networks required for macrophage
activation,” Proceedings of the National Academy of Sciences of
theUnited States ofAmerica, vol.101,no.40,pp.14461–14466,
2004.
[74] V. Perissi,A. Aggarwal, C. K. Glass,D. W. Rose, and M. G. Ro-
senfeld, “A corepressor/coactivator exchange complex re-
quired for transcriptional activation by nuclear receptors and
other regulated transcription factors,” Cell, vol. 116, no. 4, pp.
511–526, 2004.
[ 7 5 ]G .P a s c u a l ,A .L .F o n g ,S .O g a w ae ta l . ,“ AS U M O y l a t i o n -
dependent pathway mediates transrepression of inﬂammatory
response genes by PPAR-γ,” Nature, vol. 437, no. 7059, pp.
759–763, 2005.
[76] S. Ghisletti, W. Huang, S. Ogawa et al., “Parallel SUMOyla-
tion-dependent pathways mediate gene- and signal-speciﬁc
transrepression by LXRs and PPARγ,” Molecular Cell, vol. 25,
no. 1, pp. 57–70, 2007.
[77] N. Bougarne, R. Paumelle, S. Caron et al., “PPARα blocks glu-
cocorticoid receptor α-mediated transactivation but cooper-
ates with the activated glucocorticoid receptor α for transre-
pression on NF-κB,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 106, no. 18, pp.
7397–7402, 2009.
[78] N. Bougarne, R. Paumelle, G. Haegeman, B. Staels, and K. De
Bosscher, “Circumventing glucocorticoid-mediated hyperin-
sulinemia via the activation of PPARα,” Cell Cycle,v o l .8 ,n o .
15, pp. 2311–2312, 2009.
[79] N. Z. Lu and J. A. Cidlowski, “Glucocorticoid receptor iso-
forms generate transcription speciﬁcity,” Trends in Cell Biol-
ogy, vol. 16, no. 6, pp. 301–307, 2006.
[80] D. A. Stavreva, M. Wiench, S. John et al., “Ultradian hormone
stimulation induces glucocorticoid receptor-mediated pulses
of gene transcription,” Nature Cell Biology,v o l .1 1 ,n o .9 ,p p .
1093–1102, 2009.
[81] M. Y. Donath and S. E. Shoelson, “Type 2 diabetes as an
inﬂammatory disease,” Nature Reviews Immunology,v o l .1 1 ,
no. 2, pp. 98–107, 2011.
[82] N.Ouc hi,J .L.P arker ,J .J .L ugus,andK.W alsh,“ A dipokinesin
inﬂammation and metabolic disease,” Nature Reviews Im-
munology, vol. 11, no. 2, pp. 85–97, 2011.